Skip to content

Net Income at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$2.68B+8.8%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$5.24B-52.4%
AbbVie logo
AbbVieABBV
$697M-45.9%
Nuvectis Pharma, Inc. logo
Nuvectis Pharma, Inc.NVCT
-$6.05M-13.5%
Allogene Therapeutics logo
Allogene TherapeuticsALLO
-$42.61M+28.7%
Regenxbio logo
RegenxbioRGNX
-$90.05M-1,580%

Other financials

Income statement

See full
Operating income-$10.8M-131%
Net income-$10.1M-122%
EPS (diluted)-$0.18-20.0%

Balance sheet

See full
Cash & equivalents$79.3M+398%
Total debt$1.0M-2.0%
Total equity$84.4M+779%
Total assets$95.8M+382%

Cash flow

See full
Operating cash flow-$9.8M-483%
CapEx$32.5K-52.0%
Free cash flow-$9.9M-462%

Valuation

See full
Market cap$691.97M+1,008%
Enterprise value$613.75M+1,190%

Returns & leverage

See full
Return on equity-74.4%-18.6pp
Debt / equity-0.1×
Current ratio8.8×+7.0×

Where this comes from

Reported directly by Immix Biopharma, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immix Biopharma, Inc.'s net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Immix Biopharma, Inc.'s net income?
Immix Biopharma, Inc. (IMMX) reported net income of -$10.09M in Q1 2026.
How has Immix Biopharma, Inc.'s net income changed year-over-year?
Immix Biopharma, Inc.'s net income decreased by 122.1% year-over-year, from -$4.54M to -$10.09M.
What is the long-term trend for Immix Biopharma, Inc.'s net income?
Over 4 years (2021 to 2025), Immix Biopharma, Inc.'s net income has grown at a 4.8% compound annual growth rate (CAGR), from -$24.38M to -$29.4M.
What does net income mean?
Net income as the starting point for the indirect method operating cash flow reconciliation.